No Data
Relay Therapeutics Reports Interim Data for Breast Cancer Treatment
Relay Upgraded by Jefferies, Downgraded by Oppenheimer
Relay Therapeutics Faces Downgrade Over Efficacy Concerns in Competitive PI3K Inhibitor Market
Relay Therapeutics Is Maintained at Overweight by Barclays
Relay Therapeutics Price Target Raised to $17.00/Share From $14.00 by Barclays
This Johnson Controls International Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
103317720 : Meaning the up is not actual trend?
Newbee4 OP 103317720 : no more offering